Ketogama Tablet contains Alpha Ketoanalogue (NA), a critical adjunct in the management of chronic kidney disease (CKD). This medication serves as a precursor to essential amino acids, facilitating protein synthesis while minimizing nitrogenous waste accumulation, thereby reducing the metabolic burden on compromised renal function. Ketogama is primarily indicated for patients with CKD stages 3 to 5, particularly those on a low-protein diet, to delay the progression of renal impairment and mitigate uremic symptoms. The tablet aids in maintaining a balanced nitrogen metabolism, which is crucial in preventing malnutrition and muscle wasting commonly observed in advanced kidney disease. It is administered orally, with dosage tailored according to the severity of renal dysfunction and dietary protein intake. Ketogama is generally well tolerated; however, monitoring of serum electrolytes and renal parameters is recommended during therapy to detect potential imbalances or adverse effects. Contraindications include hypersensitivity to any component of the formulation and severe hepatic impairment. Ketogama should be used under strict medical supervision, particularly in patients with concomitant metabolic disorders. Its integration into a comprehensive renal care plan, including dietary management and pharmacotherapy, optimizes patient outcomes by preserving residual renal function and improving quality of life.